About the trial
The EARLY TAVR trial is no longer enrolling patients. The EARLY TAVR Trial will examine the safety and effectiveness of the Edwards SAPIEN 3/ SAPIEN 3 Ultra transcatheter heart valve (THV) versus careful observation (or clinical surveillance) in patients with severe aortic stenosis without symptoms.
The purpose of the trial is to compare results of patients that have their valves replaced early in the disease process versus patients that have the disease monitored.
Severe aortic stenosis with no symptoms
Aortic stenosis is caused by a buildup of calcium deposits on the valve leaflets, which causes the valve to narrow and reduce blood flow to the rest of your body.
Many patients with severe aortic stenosis experience symptoms, while others have no symptoms (or are asymptomatic). The symptoms of aortic stenosis are often misunderstood by patients as “normal” signs of aging. Many patients may appear to not have symptoms, but on closer examination, many do have symptoms.
Diseased aortic valve (with calcium buildup)
Questions to ask your doctor
- What screening tests will be done?
- What are the possible risks and benefits of the TAVR procedure?
- What are the possible risks and benefits of monitoring my disease (or clinical surveillance)?
- How often will I need to have follow-up visits?
- How long will the trial last?
We're here for you
We are committed to providing the highest levels of customer service to help our patients improve their quality of life. For any questions, please contact the Edwards Patient Support Center. For details about the trial, visit NCT03042104 at ClinicalTrials.gov.
Give us a call
Send us an email